Skip to main content
BLTE
NASDAQ Life Sciences

FDA Grants Priority Review to Belite Bio's Tinlarebant for Stargardt Disease, PDUFA Date Set for Feb 2027

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$180
Mkt Cap
$6.705B
52W Low
$60
52W High
$200
52W Position info
200% above low
Off High info
10% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BLTE has more than doubled off its 52-week low of $60.

Summary

The FDA accepted Belite Bio's NDA for tinlarebant in Stargardt disease type 1 and granted Priority Review, with a PDUFA date of February 12, 2027. This follows the NDA submission in June and positive Phase 3 data presented in July. Priority Review signals the FDA sees tinlarebant as a potential significant improvement over existing options for this rare retinal disease with no approved treatment. The accelerated timeline puts a definitive catalyst on the calendar, de-risking the regulatory path and bringing a potential first-to-market therapy closer to patients.

At the time of this announcement, BLTE was trading at $180.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $60.00 to $200.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BLTE - Latest Insights

BLTE
Nov 20, 2026, 8:05 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $146.06
Real-time Price: $122.06 info
Change: -$24.00 (-16%) info
Market Cap: $6.134B info
BLTE
Nov 20, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $146.06
Real-time Price: $122.06 info
Change: -$24.00 (-16%) info
Market Cap: $6.134B info
BLTE
Nov 12, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $156.00
Real-time Price: $122.06 info
Change: -$33.94 (-22%) info
Market Cap: $6.134B info
BLTE
Sep 08, 2026, 6:06 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $193.61
Real-time Price: $122.06 info
Change: -$71.55 (-37%) info
Market Cap: $6.134B info
BLTE
Aug 12, 2026, 9:50 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $178.94
Real-time Price: $122.06 info
Change: -$56.88 (-32%) info
Market Cap: $6.134B info